Today, we commemorate #Juneteenth, the United States’ second Independence Day. At Orca Bio, we reflect on and celebrate this monumental day and significant milestone in the enduring fight for freedom. Join us in learning more:

We're pleased to welcome Mike Hirschmann to #TeamOrcaBio as SVP of U.S. Commercial to lead the company’s U.S. commercial launch planning and execution!. Mike brings 30+ years of biopharma experience at companies including Legend Biotech, Celgene and Puma Biotechnology.

Orca Bio is thrilled to announce the appointment of Steve Gavel as Chief Commercial Officer and Allison Frisbee as SVP of Legal to support the company as it advances its pipeline of high-precision cell therapies. To read more:

Welcome Andrea Blank to #TeamOrcaBio as VP of Medical Affairs! Andrea brings a wealth of strategic & clinical expertise in #celltherapy. At Orca Bio, she will be responsible for shaping our Medical Affairs strategy as we advance our pipeline of investigational cell therapies.

On #WorldBloodCancerDay and every day, we are on a mission to transform the lives of patients and families affected by #bloodcancer through the development of our pipeline of high-precision cell therapies. #oncology #hematology #celltherapy

On #ClinicalTrialsDay, we express our deepest gratitude to the patients who participate in clinical trials, & the researchers committed to saving & improving lives. Together, they help to further potentially life-saving clinical research & bring hope to countless others #CTD2025

Orca Bio is pleased to announce the appointment of co-founder Nathaniel Fernhoff, Ph.D. as Chief Executive Officer. In addition, co-founder and Chief Operating Officer Jeroen Bekaert, Ph.D. has been appointed President. Read more here:

May is National Cancer Research Month, a time to highlight the research that furthers our understanding of cancers to ultimately help the millions of people impacted. Hear from, Josie O’Shea, on the vital role research plays in advancing cancer science and medicine. #NCRM25

Orca Bio’s Head of Global Market Access, Head of Business Development, and Head of Corporate Communications will be in San Diego this week for #FiercePharmaEngage.

This #AMLWorldAwarenessDay, we are bringing attention to the ~22,010 people who will be diagnosed with acute myeloid leukemia (#AML) in 2025 and patients who have already been living with this disease. If you have been diagnosed with AML, you are not alone in your treatment

We’re on the ground in Florence, Italy for the 51st Annual Meeting of the EBMT. Join us as we present results from the pivotal Phase 3 Precision-T study of Orca-T and other updates related to our lead investigational T-cell immunotherapy. #EBMT25

Today we announced positive results from the pivotal Phase 3 study of investigational Orca-T versus conventional allogeneic stem cell transplant for the treatment of hematologic malignancies. The results will be presented at the 51st Annual Meeting of the EBMT on April 2, 2025.

We are thrilled to announce Jesus Varela as Head of People at Orca Bio. Jesus brings over two decades of experience and will be instrumental in scaling our team as we progress toward the commercialization of our investigational #celltherapies. Welcome to #TeamOrcaBio, Jesus!

This #NationalCaregiversDay, we celebrate the dedicated individuals – approximately 100 million US adults – who support their loved ones through the patient journey. Explore caregiver resources from @power4patients:

#TeamOrcaBio is on the ground in Honolulu for the 2025 Tandem Meetings of the ASTCTand CIBMTR (Center for International Blood & Marrow Transplant Research). Come check us out at Booth #201! . Learn more about the four presentations highlighting our investigational allogeneic

Orca Bio will present results from the pivotal Phase 3 Precision-T study of its investigational Orca-T in people with hematological malignancies at #EBMT25. The study met its primary endpoint of an improvement in survival free of moderate-to-severe cGvHD with Orca-T vs.

Each year, ~1.24M #bloodcancer cases occur worldwide. This #WorldCancerDay, we unite to raise awareness and spur action toward reducing the global impact of this deadly disease. Visit @LLSusa Community for resources: . #patientsfirst #unitedbyunique

#ICYMI, earlier this week Orca Bio’s CEO, Ivan Dimov, presented our strategic priorities and anticipated milestones for the year ahead and beyond at the 43rd Annual J.P. Morgan Healthcare Conference #JPM25. #bloodcancer #oncology #hematology

We’re proud to partner with @nmdp_biotherap in our shared mission to transform the lives of people with blood cancer. Blood stem cell donors like Shanon are a critical part of this journey, and their selflessness inspires us every day. Join the movement:

On Jan. 13 at 8 AM PT, Orca Bio’s co-founder & CEO, Ivan Dimov, will present at #JPM25. We look forward to connecting with the #biotech investor community & other industry leaders about our anticipated milestones and the 2025 #celltherapy landscape.